Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Aadi Bioscience (AADI)
NASDAQ:AADI
Holding AADI?
Track your performance easily
AADI Stock Chart & Stats
Day’s Range― - ―
52-Week Range$1.21 - $3.81
Previous CloseN/A
Volume191.44K
Average Volume (3M)617.05K
Market Cap
$77.50M
Enterprise Value-$5.97M
Total Cash (Recent Filing)$4.46M
Total Debt (Recent Filing)$1.10M
Price to Earnings (P/E)―
Beta0.25
Next Earnings
Mar 13, 2025EPS Estimate
-0.47Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.29
Shares Outstanding24,680,708
10 Day Avg. Volume263,281
30 Day Avg. Volume617,055
Standard Deviation0.22
R-Squared0.02
Alpha-0.00088
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)3.09
Price to Cash Flow (P/CF)-1.20
P/FCF Ratio0.00
Enterprise Value/Market Cap-0.08
Enterprise Value/Revenue-0.24
Enterprise Value/Gross Profit-0.28
Enterprise Value/Ebitda0.10
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Aadi Bioscience News
PremiumCompany Announcements
Aadi Bioscience’s Strategic Agreements and Funding Moves
PremiumCompany Announcements
Aadi Bioscience Reports Q3 2024 Earnings and GrowthOwnership Overview
31.18% Insiders
4.33% Mutual Funds
38.61% Other Institutional Investors
22.69% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
AADI FAQ
What was Aadi Bioscience’s price range in the past 12 months?
Aadi Bioscience lowest stock price was $1.21 and its highest was $3.81 in the past 12 months.
What is Aadi Bioscience’s market cap?
Aadi Bioscience’s market cap is $77.50M.
When is Aadi Bioscience’s upcoming earnings report date?
Aadi Bioscience’s upcoming earnings report date is Mar 13, 2025 which is in 41 days.
How were Aadi Bioscience’s earnings last quarter?
Aadi Bioscience released its earnings results on Nov 06, 2024. The company reported -$0.46 earnings per share for the quarter, missing the consensus estimate of -$0.458 by -$0.002.
Is Aadi Bioscience overvalued?
According to Wall Street analysts Aadi Bioscience’s price is currently Overvalued.
Does Aadi Bioscience pay dividends?
Aadi Bioscience does not currently pay dividends.
What is Aadi Bioscience’s EPS estimate?
Aadi Bioscience’s EPS estimate is -0.47.
How many shares outstanding does Aadi Bioscience have?
Aadi Bioscience has 24,680,708 shares outstanding.
What happened to Aadi Bioscience’s price movement after its last earnings report?
Aadi Bioscience reported an EPS of -$0.46 in its last earnings report, missing expectations of -$0.458. Following the earnings report the stock price went up 6.533%.
Which hedge fund is a major shareholder of Aadi Bioscience?
Currently, no hedge funds are holding shares in AADI
---
Aadi Bioscience Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Blogger Sentiment
Bearish
AADI Sentiment 100%
Sector Average 71%
Sector Average 71%
Crowd Wisdom
Very Negative
Last 7 Days ▼ 2.0%
Last 30 Days ▼ 4.8%
Last 30 Days ▼ 4.8%
Technicals
SMA
Positive
20 days / 200 days
Momentum
83.62%
12-Months-Change
Fundamentals
Return on Equity
-65.95%
Trailing 12-Months
Asset Growth
-38.64%
Trailing 12-Months
Company Description
Aadi Bioscience
Aerpio Pharmaceuticals Inc. is a biopharmaceutical company, which engages in the research and development of treatments for ocular diseases. Its product candidate is AKB-9778, a small molecule activator of the Tie2 pathway, which completed the Phase 2a clinical trial for the treatment of diabetic retinopathy. It also develops ARP-1536, a humanized monoclonal antibody that is in preclinical development stage for the treatment of diabetic vascular complications; and AKB-4924, a selective stabilizer of hypoxia-inducible factor-1 alpha, which has completed a single ascending dose clinical trial for the treatment of inflammatory bowel disease. The company was founded by Joseph H. Garder on November 17, 2011 and is headquartered in Cincinnati, OH.
---
Technical Analysis
Scholar Rock Holding
―
Hookipa Pharma
―
Bicycle Therapeutics
―
TScan Therapeutics
―
Immuneering
―
---